 |
Advertisement
|
BROWSE topics
Risedronate sodium - Actonel®
Usual Dosing (Adults) |
||
|
Treatment of Postmenopausal Osteoporosis: one 5 mg tablet orally, taken daily or one 35 mg tablet orally, taken once a week or one 75 mg tablet orally, taken on two consecutive days for a total of two tablets each month or one 150 mg tablet orally, taken once a month Prevention of Postmenopausal Osteoporosis: one 5 mg tablet orally, taken daily or one 35 mg tablet orally, taken once a week or alternatively, one 75 mg tablet orally, taken on two consecutive days for a total of two tablets each month may be considered or alternatively, one 150 mg tablet orally, taken once a month may be considered Treatment to Increase Bone Mass in Men with Osteoporosis: one 35 mg tablet orally, taken once a week . Treatment and Prevention of Glucocorticoid-Induced Osteoporosis: one 5 mg tablet orally, taken daily. Treatment of Paget’s Disease: The recommended treatment regimen is 30 mg orally once daily for 2 months. Retreatment may be considered (following post-treatment observation of at least 2 months) if relapse occurs, or if treatment fails to normalize serum alkaline phosphatase. For retreatment, the dose and duration of therapy are the same as for initial treatment. No data are available on more than 1 course of retreatment |
||
Renal Dosing |
||
|
||
Hemodialysis |
||
|
||
Disclaimer |
||
| The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer | ||
Don't forget to check out the extensive health section.... |
||
|
